Filing Flows › Health Care › Emmaus Life Sciences (EMMA)
Emmaus Life Sciences (EMMA) earnings and revenue breakdown
Latest: Q2 2026 · 10-Q filed Aug 14, 2026 · Emmaus Life Sciences (EMMA) Q2 2026 earnings results →
Q2 2026 Revenue up 124% year over year to $6.3M · 21¢ of every $1 of revenue kept as net profit · operating margin 60.0%
Emmaus Life Sciences made $6.3M in Q2 2026 (+124% Y/Y): Endari US $6.0M, Endari International $295K, Product and Service Other $22K. Operating margin 60.0%, net earnings $1.3M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 14, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $6.3M in Q2 2026, up 124% year over year and up 219% from the previous quarter. Endari US was the largest line at 95% of revenue. Endari US added $3.7M year over year (up 158%), 105% of the total change. Endari International declined 38%.
Gross margin was 94.6%, down 0.1 points from Q2 2025. Operating profit was $3.8M, a 60.0% margin (up 73.1 points year over year). Operating expenses fell 28% while revenue rose 124%. The fastest-growing cost line was Research & development (+107%). Net earnings were $1.3M. The effective tax rate was -0.1%.
Operating cash flow was $1.7M, 126% of net earnings. Non-cash charges added back $14K of depreciation. Working capital and other items added $340K.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 10-Q | Aug 14, 2026 | $6.3M | +124% | 60.0% | $1.3M | $1.7M |
| Q1 2026 | 10-Q | May 15, 2026 | $2.0M | -18% | -41.5% | −$3.3M | −$344K |
| Q4 2025 | 10-K | Mar 31, 2026 | $3.9M | +17% | 23.0% | −$2.0M | $2.2M |
| Q3 2025 | 10-Q | Nov 14, 2025 | $3.4M | -38% | 20.6% | −$2.1M | $409K |
| Q2 2025 | 10-Q | Aug 14, 2025 | $2.8M | -48% | -13.1% | −$1.1M | −$2.9M |
| Q1 2025 | 10-Q | May 15, 2025 | $2.4M | -4% | -40.7% | −$2.3M | $279K |
| Q4 2024 | 10-K | Apr 14, 2025 | $3.3M | -53% | -16.9% | −$1.7M | $343K |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Emmaus Life Sciences
Emmaus Life Sciences, Inc. is a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease. Endari® (L-glutamine oral powder), indicated to reduce the acute complications of sickle cell disease in adults and children 5 years and older, is approved for marketing in the United States, Israel, Kuwait, Qatar, the United Arab Emirates, Bahrain and Oman and is available on a named patient or early access basis in France, the Netherlands, and the Kingdom of Saudi Arabia, where Emmaus’ application for marketing authorization is awaiting final action by the Saudi Food & Drug Authority. For more information, please visit www.emmausmedical.com.
In its own words, from its 8-K, filed Aug 14, 2026.
Emmaus Life Sciences against its Pharmaceutical Preparations peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +124% against the peers' median +10%. Operating margin: 60.0% against the peers' median 30.7%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| EMMA Emmaus Life Sciences | Q2 2026 | $6.3M | +124% | 60.0% |
| JNJ Johnson & Johnson | Q3 2026 | $25.4B | +6% | 0.1% |
| LLY ELI Lilly | Q3 2026 | $24.4B | +39% | 34.5% |
| MRK Merck | Q3 2026 | $18.1B | +5% | 30.7% |
| ABBV AbbVie | Q3 2026 | $17.4B | +10% | 36.0% |
| PFE Pfizer | Q3 2026 | $16.6B | -0.4% | 20.4% |
| BMY Bristol Myers Squibb | Q3 2026 | $13.1B | +7% | 19.4% |
| ABT Abbott Laboratories | Q3 2026 | $13.0B | +14% | 10.4% |
| REGN Regeneron Pharmaceuticals | Q3 2026 | $5.1B | +36% | 40.0% |
Source: Emmaus Life Sciences 10-Q on SEC EDGAR · CIK 822370 · Pharmaceutical Preparations
More on EMMA
History
Every quarter: Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results · Q4 2024 results